Are Sandu Pharma. latest results good or bad?

Sandu Pharmaceuticals has reported its financial results for the quarter ending March 2025, revealing a notable decline in performance metrics. The company's net sales for this quarter were recorded at Rs 14.07 crore, which represents a significant decrease compared to the average net sales of Rs 17.18 crore over the previous four quarters. This figure marks the lowest net sales for Sandu Pharmaceuticals in the last five quarters, indicating a concerning trend in sales performance.
In terms of profitability, the consolidated net profit also experienced a decline, with a reported decrease of 41.07% compared to the previous quarter. The operating profit, excluding other income, saw a similar downward trend, declining by 54.55%. Additionally, the operating profit margin, which stood at 3.20% in the previous quarter, has also faced a reduction.

Overall, these results suggest that Sandu Pharmaceuticals is facing challenges in its operational performance, as reflected in the declining sales and profit figures. Furthermore, the company saw an adjustment in its evaluation over the past three months, indicating a shift in its financial standing.